TEV:F:F-Teva Pharmaceutical Industries Limited (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 13

Change

+0.70 (+5.69)%

Market Cap

USD 14.69B

Volume

4.12K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRK:F Merck & Company Inc

-0.50 (-0.32%)

USD 66.78B
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 65.62B
ZOE:F Zoetis Inc

+2.00 (+1.31%)

USD 64.18B
TKD:F Takeda Pharmaceutical Company ..

-0.21 (-0.87%)

USD 39.41B
TKDA:F Takeda Pharmaceutical Company ..

-0.30 (-2.46%)

USD 38.72B
H6D0:F Haleon PLC

-0.04 (-1.12%)

USD 35.13B
H6D:F Haleon PLC

-0.10 (-1.36%)

USD 35.12B
SH0:F Shionogi & Co. Ltd

+0.40 (+0.92%)

USD 12.76B
NB3:F Neurocrine Biosciences Inc

-0.80 (-0.61%)

USD 12.70B
RDDA:F Dr. Reddy's Laboratories Limit..

-1.00 (-1.52%)

USD 11.53B

ETFs Containing TEV:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.92% 84% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.92% 80% B- 89% A-
Trailing 12 Months  
Capital Gain 61.69% 92% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.69% 88% B+ 86% B+
Trailing 5 Years  
Capital Gain -4.76% 63% D 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.76% 41% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain 4.22% 77% C+ 63% D
Dividend Return 4.22% 72% C 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.18% 63% D 52% F
Risk Adjusted Return 19.04% 70% C- 54% F
Market Capitalization 14.69B 97% N/A 89% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector